19499-61-7

Basic information

• Product Name: (3-Nitrobenzyl)methylamine
• Synonyms: 3-Nitro-N-methylbenzylamine;N-Methyl-N-(3-nitrobenzyl)amine ,97%;(3-Nitrobenzyl)methy;N-Methyl-3-nitrobenzylaMine, 95%;N-Methyl-1-(3-nitrophenyl)MethanaMine;(3-Nitrobenzyl)MethylaMine, 98%+;N-METHYL-N-(3-NITROBENZYL)AMINE;(3-NITROBENZYL)METHYLAMINE
• CAS NO: 19499-61-7
• Molecular Formula: C₈H₁₀N₂O₂
• Molecular Weight: 166.18
• Product Categories: Polyamines
• Mol File: 19499-61-7.mol

Chemical Properties

• Melting Point: 160 °C
• Boiling Point: 128 °C
• Flash Point: 119.7 °C
• Appearance: /Oil
• Density: 1.162 g/cm³
• Vapor Pressure: 0.00546mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.94±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: (3-Nitrobenzyl)methylamine(CAS DataBase Reference)
• NIST Chemistry Reference: (3-Nitrobenzyl)methylamine(19499-61-7)
• EPA Substance Registry System: (3-Nitrobenzyl)methylamine(19499-61-7)

Safety Data

• HazardClass: 8
• Hazardous Substances Data: 19499-61-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(3-Nitrobenzyl)methylamine is used as an important intermediate for the synthesis of various organic compounds. Its versatile chemical structure allows it to be a key component in the creation of a wide range of molecules.
Used in Agrochemicals:
In the agrochemical industry, (3-Nitrobenzyl)methylamine is used as a vital raw material for the development of new pesticides and other agricultural chemicals. Its incorporation into these products helps improve their effectiveness and selectivity, contributing to more efficient and environmentally friendly agricultural practices.
Used in Pharmaceutical Industry:
(3-Nitrobenzyl)methylamine plays a significant role in the pharmaceutical industry as a building block for the synthesis of various drugs. Its unique structure can be manipulated to create molecules with specific biological activities, making it a valuable asset in the development of new medications.
Used in Dye Industry:
(3-Nitrobenzyl)methylamine is also utilized in the dyestuff industry as a starting material for the production of different types of dyes. Its chemical properties enable the creation of dyes with specific color characteristics and stability, which are essential for various applications, including textiles, plastics, and printing inks.

InChI:InChI=1/C8H10N2O2/c1-9-6-7-3-2-4-8(5-7)10(11)12/h2-5,9H,6H2,1H3/p+1

Upstream product

• 121004-44-2 N-methyl-1-(3-nitrophenyl)methanimine 
• 7697-37-2 nitric acid 
• 103-67-3 benzyl-methyl-amine 
• 99-61-6 3-nitro-benzaldehyde 
• 74-89-5 methylamine 
• 100-46-9 benzylamine 
• 100-44-7 benzyl chloride 
• 3695-02-1 N-benzyl-N-methyl-p-toluenesulfonamide 
• 1576-37-0 N-benzyl-p-toluenesulfonamide 
• 3958-57-4 1-bromomethyl-3-nitrobenzene 
• 98760-23-7 C₈H₉BrN₂O₂ 
• 593-51-1 methylamine hydrochloride 
• 619-23-8 3-Nitrobenzyl chloride 

Downstream Products

• 70972-96-2 N-Chloro-N-methyl-m-nitrobenzylamin 
• 98760-23-7 C₈H₉BrN₂O₂ 
• 943742-17-4 methyl-(3-nitro-benzyl)-carbamic acid benzyl ester 
• 1147092-64-5 (3,4-dimethoxyphenyl)-(4-{[methyl-(3-nitrobenzyl)amino]methyl}phenyl)methanone 
• 1459259-62-1 N-[3-[[2-(2,3-dihydro-1,4-benzodioxin-5-yloxy)ethylmethylamino]methyl]phenyl]benzenesulphonamide 
• 1459261-59-6 2-(2,3-dihydro-1,4-benzodioxin-5-yloxy)-N-metyl-N-(3-nitrobenzyl)ethylamine 

Relevant articles and documents

Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent

Pragmatic insertion of pargyline, a LSD1 inhibitor, as a surface recognition part in the HDAC inhibitory pharmacophore was planned in pursuit of furnishing potent antiprostate cancer agents. Resultantly, compound 14 elicited magnificent cell growth inhibi

Novel chiral bis-phosphoramides as organocatalysts for tetrachlorosilane-mediated reactions

The formation of novel chiral bidentate phosphoroamides structures able to promote Lewis base-catalyzed Lewis acid-mediated reactions was investigated. Two different classes of phosphoroamides were synthetized: the first class presents a phthalic acid/pri

Phenyl ether- and aniline-containing 2-aminoquinolines as potent and selective inhibitors of neuronal nitric oxide synthase

Excess nitric oxide (NO) produced by neuronal nitric oxide synthase (nNOS) is implicated in neurodegenerative disorders. As a result, inhibition of nNOS and reduction of NO levels is desirable therapeutically, but many nNOS inhibitors are poorly bioavailable. Promising members of our previously reported 2-aminoquinoline class of nNOS inhibitors, although orally bioavailable and brain-penetrant, suffer from unfavorable off-target binding to other CNS receptors, and they resemble known promiscuous binders. Rearranged phenyl ether- and aniline-linked 2-aminoquinoline derivatives were therefore designed to (a) disrupt the promiscuous binding pharmacophore and diminish off-target interactions and (b) preserve potency, isoform selectivity, and cell permeability. A series of these compounds was synthesized and tested against purified nNOS, endothelial NOS (eNOS), and inducible NOS (iNOS) enzymes. One compound, 20, displayed high potency, selectivity, and good human nNOS inhibition, and retained some permeability in a Caco-2 assay. Most promisingly, CNS receptor counterscreening revealed that this rearranged scaffold significantly reduces off-target binding.

SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES

Sulphonamide derivatives of benzylamine of formula (I), wherein A represents phenyl unsubstituted or substituted; or 9- or 10-membered bicyclic group, linked to —(O)x—(CH2)y— through one of its aromatic carbon atoms, consisting of benzene ring fused with -membered heteroaromatic ring containing 1 or 2 heteroatoms independently selected from the group consisting of N and O, wherein such bicyclic group is unsubstituted or substituted or with 5- or 6-membered non-aromatic heterocyclic ring having 1 or 2 O atoms, wherein heterocyclic ring is unsubstituted or substituted with one or more C1-C3-alkyls; D represents a group selected from: phenyl unsubstituted or substituted; naphthyl unsubstituted or substituted; thiophene unsubstituted or substituted; bicyclic group consisting of imidazolering fused with 5-membered non-aromatic carbocyclic ring; bicyclic group consisting of benzene ring fused with 5-membered heteroaromatic ring, having 1 or 2 heteroatoms independently selected from the group consisting of N, O and S, unsubstituted or substituted and linked to sulphonamide moiety through one of carbon atoms of benzene ring; and bicyclic group consisting of benzene ring fused with—or 6-membered non-aromatic heterocyclic ring having 1 or 2 heteroatoms independently selected from the group consisting of N and O, unsubstituted or substituted, and linked to sulphonamide moiety through one of carbon N atoms of benzene ring; R represents H or —CH 3; x is 0 or 1; y is 2 or 3; and pharmaceutically acceptable salts and solvates thereof, with the provisos that if x is 0 and y is 2, then D is naphthyl unsubstituted or substituted with one halogen atom, and if R represents —CH 3, then A is not unsubstituted or substituted phenyl. The compounds can be used in the treatment and/or prophylaxis of central nervous system disorders.

SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES

Sulphonamide derivatives o f benzylamine of formula (I), wherein A represents phenyl unsubstituted or substituted;or 9-or 10-membered bicyclic group, linked to -(O)x - (CH2)y -through one of its aromatic carbon atoms, consisting of benzene ring fused with -membered heteroaromatic ring containing 1 or 2 heteroatoms independently selected from the group consisting of N and O, wherein such bicyclic group is unsubstituted or substituted or with 5-or 6-membered non-aromaticheterocyclic ring having 1 or 2 O atoms, wherein heterocyclic ring is unsubstituted or substituted with one or more C1-C3 - alkyls; D represents a group selected from:phenyl unsubstituted or substituted; naphthyl unsubstituted or substituted;thiophene unsubstituted or substituted;bicyclic group consisting of imidazolering fused with5-membered non-aromatic carbocyclic ring; bicyclic group consisting of benzene ring fused with 5-membered heteroaromatic ring, having 1 or 2heteroatoms independently selected from the group consisting of N, O and S, unsubstituted or substituted and linked to sulphonamide moiety through one of carbon atoms of benzene ring;and bicyclic group consisting of benzene ring fused with -or 6-membered non-aromatic heterocyclic ring having 1 or 2heteroatoms independently selected from the group consisting of N and O, unsubstituted or substituted, and linked to sulphonamide moiety through one of carbon atoms of benzene ring;R represents H or -CH3;x is 0 or 1 ;yis 2 or 3;and pharmaceutically acceptable salts and solvates thereof, with the provisos that if x is 0 and y is 2, then D is naphthyl unsubstituted or substituted with one halogen atom, and if R represents -CH3, then A is not unsubstituted or substituted phenyl. The compounds can be used in the treatment and/or prophylaxis of central nervous system disorders

DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR

This invention is directed to compounds of formula (I): to pharmaceutical compositions comprising them; to combination products comprising them; and to their use in therapy.

QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, X1, R6, r and R7 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

Assessment of a reductive amination route to methyl(3-nitrobenzyl)amine hydrochloride

During the development of a sodium borohydride mediated reductive animation of 3-nitrobenzaldehyde with methylamine, studies revealed that partial reduction of the nitro group occurred, and potentially dangerous azo- and azoxy-containing products were gen

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.

Aniline derivatives possessing an inhibitory effect of nitric oxide synthase

Compounds represented by the general formula (1): ? (where R1is SR6or NR7R8, where R6is typically an alkyl group having 1-6 carbon atoms, R7is a hydrogen atom, an alkyl group having 1-6 carbon atoms or a nitro group, and R8is a hydrogen atom or an alkyl group having 1-6 carbon atoms; R2and R3are each typically a hydrogen atom or an alkyl group having 1-6 carbon atoms; R4is a hydrogen atom, an alkyl group having 1-6 carbon atoms or an amidino group of which the amine portion may be substituted by an alkyl or nitro group; R5is a hydrogen atom or an alkyl group having 1-6 carbon atoms; Y1, Y2, Y3and Y4which may be the same or different are each typically a hydrogen atom, a halogen atom or an alkoxy group having 1-6 carbon atoms; n and m are each an integer of 0 or 1), or possible stereoisomers or optically active forms of the compounds or pharmaceutically acceptable salts thereof. The compounds possess a potent nitric oxide synthase inhibiting activity and are useful as therapeutics of cerebrovascular diseases.